The weak promoter could be completely repressed by the dispersed methylated CpG, and the transcription stopped completely, which was why many studies have suggested that patients with MGMT promoter methylation have better efficacy with TMZ in glioblastoma [37]. The gene discussed is MGMT; the disease is glioblastoma.